Study guide
7.5 Gynecologic Oncology & Pelvic Mass Evaluation
Medical Council of Canada Qualifying Examination Part I MCCQE Part I
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Overview, Blueprint & Canadian Medical Practice
1.1 MCCQE Part I Format, Scoring (439 Scale), & Strategy 1.2 The MCC Blueprint Matrix: Dimensions of Care & Physician Activities 1.3 Canadian Healthcare System, CanMEDS Roles, & Interprofessional Care 1.4 Evidence-Based Medicine, Study Design, & Clinical Statistics
2 Chapter 2: Population Health, Health Promotion & Preventive Care
2.1 Canadian Task Force on Preventive Health Care (CTFPHC) Screening Guidelines 2.2 Immunization Schedules (NACI) & Vaccine-Preventable Diseases across Lifespan 2.3 Disease Prevention, Lifestyle Counselling, & Harm Reduction 2.4 Outbreak Management, Disease Surveillance, & Infection Control 2.5 Occupational, Environmental, & Travel Medicine in Canada
3 Chapter 3: Internal Medicine — Cardiovascular & Respiratory Systems
3.1 Hypertension Canada 2020/2025 Guidelines, Dyslipidemia, & Primary Prevention 3.2 Ischemic Heart Disease, Acute Coronary Syndromes, & Heart Failure Management 3.3 Arrhythmias, Valvular Heart Disease, & Infective Endocarditis 3.4 Asthma, COPD, & Respiratory Failure (CTS Guidelines) 3.5 Thromboembolic Disease (DVT/PE), Pneumonia, & Pleural Effusions
4 Chapter 4: Internal Medicine — GI, Endocrine, Renal & Hematology/Oncology
4.1 Gastrointestinal Disorders, Acute Abdomen, & Liver/Biliary Disease 4.2 Diabetes Canada 2020/2025 Guidelines & Glycemic Management 4.3 Thyroid, Adrenal, Pituitary, & Electrolyte Disturbances 4.4 Acute Kidney Injury (AKI), Chronic Kidney Disease (CKD), & Nephrology 4.5 Hematology, Anemia Evaluation, Transfusion Medicine, & Common Cancers
5 Chapter 5: General Surgery, Orthopedics, & Emergency Care
5.1 Surgical Evaluation, Preoperative Clearance, & Postoperative Complications 5.2 Trauma Management (ATLS Protocol) & Burns 5.3 Acute Surgical Conditions (Appendicitis, Cholecystitis, Bowel Obstruction) 5.4 Fractures, Dislocations, Joint Pain, & Musculoskeletal Emergencies 5.5 Vascular Emergencies, Wound Care, & Shock Recognition
6 Chapter 6: Pediatrics & Adolescent Health
6.1 Pediatric Growth, Developmental Milestones, & Well-Child Examinations 6.2 Neonatal Resuscitation, Jaundice, & Common Congenital Anomalies 6.3 Pediatric Respiratory Emergencies (Croup, Bronchiolitis, Asthma) 6.4 Common Pediatric Infections, Exanthems, & Fever of Unknown Origin 6.5 Pediatric Abdominal Pain, Dehydration, & Fluid Management
7 Chapter 7: Obstetrics & Gynecology
7.1 Routine Antepartum Care, Screening, & Prenatal Diagnosis (SOGC Guidelines) 7.2 Medical Complications of Pregnancy (Preeclampsia, Gestational Diabetes, Infections) 7.3 Labor, Intrapartum Management, & Postpartum Complications/Hemorrhage 7.4 Abnormal Uterine Bleeding, Gynecologic Infections, & Contraception/Menopause 7.5 Gynecologic Oncology & Pelvic Mass Evaluation
8 Chapter 8: Psychiatry & Mental Health
8.1 Mood Disorders (Depression, Bipolar) & Suicide Risk Assessment 8.2 Anxiety Disorders, OCD, PTSD, & Somatic Symptom Disorders 8.3 Psychotic Disorders & Schizophrenia Management 8.4 Substance Use Disorders, Withdrawal Syndromes, & Harm Reduction 8.5 Pediatric, Perinatal, & Geriatric Psychiatry (Cognitive Impairment / Delirium)
9 Chapter 9: Neurology, Rheumatology, & Dermatology
9.1 Acute Stroke, TIA, & Neurovascular Emergencies 9.2 Headaches, Seizures, Movement Disorders, & Neuromuscular Disease 9.3 Inflammatory Arthritides (RA, Gout, SpA) & Systemic Autoimmune Diseases (SLE, Vasculitis) 9.4 Common Dermatologic Conditions, Cutaneous Manifestations of Systemic Disease, & Skin Cancers 9.5 Musculoskeletal Soft Tissue Injuries, Back Pain, & Physical Medicine
10 Chapter 10: Legal, Ethical, & Professional Behaviours in Canadian Practice
10.1 Informed Consent, Capacity Assessment, & Substitute Decision-Making (CMPA) 10.2 Medical Confidentiality, Privacy Laws (PIPEDA/PHIPA), & Disclosure of Harm 10.3 CMA Code of Ethics, Professionalism, & Physician Health/Boundary Issues 10.4 Mandatory Reporting (Child/Elder Abuse, Driving Safety, Fitness to Practice) & Quality/Safety
7.5 Gynecologic Oncology & Pelvic Mass Evaluation
Key Takeaways Explain This Topic AI
Cervical cancer screening in Canada relies on cytology or primary HPV DNA testing; persistent high-risk HPV types 16 and 18 cause >70% of cervical dysplasias and invasive carcinomas.
Endometrial carcinoma is the most common gynecologic malignancy, presenting with postmenopausal bleeding; major risk factors involve prolonged unopposed estrogen (obesity, nulliparity, PCOS, tamoxifen, Lynch syndrome).
Epithelial ovarian cancer (serous sub-type) predominates in postmenopausal women with CA-125 elevation and complex ultrasound features, triaged using the Risk of Malignancy Index (RMI >200 warrants gynecologic oncology referral).
Malignant germ cell tumors (yolk sac tumor with elevated AFP, dysgerminoma with elevated LDH, choriocarcinoma with elevated β-hCG) typically affect adolescents and young women under 30 years.
Lichen Sclerosus is a chronic autoimmune vulvar dermatosis carrying a 4–5% risk of transformation to vulvar squamous cell carcinoma, requiring high-potency topical corticosteroids (clobetasol) and surveillance.
Last updated: July 2026
Gynecologic Oncology & Pelvic Mass Evaluation
Gynecologic malignancies represent a significant cause of female cancer morbidity and mortality. Early recognition, accurate triage of adnexal masses, and adherence to SOGC and FIGO staging guidelines are key competencies evaluated on the MCCQE Part I.
Cervical Cancer Screening, HPV, & Dysplasia
Cervical cancer is almost universally caused by persistent infection with high-risk oncogenic strains of Human Papillomavirus (HPV) , predominantly types 16 and 18 (responsible for >70% of invasive cervical cancers).
Oncogenic Mechanism
E6 Oncoprotein : Binds and promotes ubiquitin-mediated degradation of the p53 tumor suppressor protein.
E7 Oncoprotein : Binds and inactivates the Retinoblastoma (Rb) tumor suppressor protein, accelerating cell cycle progression from G1 to S phase.
Canadian Screening Guidelines (SOGC)
Initiation : Cytology (Pap test) screening starts at age 21 or 25 (depending on provincial guidelines) for individuals who are or have been sexually active.
Frequency : Cytology every 3 years until age 65.
Transition to Primary HPV DNA Screening : Canadian guidelines recommend transitioning to primary HPV testing every 5 years for individuals aged 30–65.
Bethesda System Cytology Triage :
ASC-US (Atypical Squamous Cells of Undetermined Significance): Repeat Pap in 6 months OR perform reflex HPV DNA testing. If HPV positive → Colposcopy.
LSIL (Low-grade Squamous Intraepithelial Lesion): Corresponds to CIN-1. Referral for colposcopy.
HSIL (High-grade Squamous Intraepithelial Lesion): Corresponds to CIN-2 or CIN-3. Immediate colposcopy; managed with Loop Electrosurgical Excision Procedure ( LEEP ) or cervical cone biopsy.
AGC (Atypical Glandular Cells): High risk of endometrial or cervical adenocarcinoma. Requires colposcopy, endocervical curettage (ECC), AND endometrial biopsy (Pipelle).
Endometrial Carcinoma
Endometrial carcinoma is the most common gynecologic cancer in North America.
Pathophysiology & Risk Factors
The primary driver for Type I endometrioid carcinoma is prolonged, unopposed estrogen exposure without sufficient progestin counter-regulation:
Obesity : Increased peripheral aromatization of androstenedione to estrone in adipose tissue.
Endogenous Estrogen : Nulliparity, early menarche (<12 yrs), late menopause (>55 yrs), polycystic ovary syndrome (PCOS, chronic anovulation).
Exogenous Estrogen : Estrogen-only menopausal hormone therapy, Tamoxifen therapy (selective estrogen receptor modulator that acts as an agonist on the endometrium).
Genetic Syndromes : Lynch Syndrome (Hereditary Non-Polyposis Colorectal Cancer - HNPCC), carrying up to a 60% lifetime risk of endometrial cancer.
Protective Factors : Multiparity, combined oral contraceptive pills (progestin component stabilizes endometrium), physical activity.
Clinical Presentation & Staging
Symptom : >90% of cases present with postmenopausal bleeding (PMB) or abnormal perimenopausal bleeding.
Diagnosis : Endometrial tissue biopsy (Pipelle sampling) or Dilation & Curettage (D&C).
FIGO Surgical Staging : Total Abdominal Hysterectomy + Bilateral Salpingo-Oophorectomy (TAH-BSO) + pelvic/para-aortic lymph node dissection.
Evaluation of Pelvic & Adnexal Masses
When evaluating an adnexal mass, the primary goal is distinguishing benign functional cysts from malignant neoplasms.
Transvaginal Ultrasound (TVUS) Diagnostic Characteristics
Feature Benign Ultrasonographic Features Malignant Ultrasonographic Features
Structure Simple cyst, unilocular, smooth thin wall (<3 mm) Multilocular, thick septations (>2–3 mm), solid components
- Echogenicity Anechoic fluid Complex, heterogeneous, internal papillary projections
- Vascularity Low color Doppler vascular flow High-flow internal vascularity with low resistance
- Associated Findings Absence of peritoneal fluid Ascites , peritoneal nodularity, bilateral masses
- Ovarian Tumor Markers by Age Group
Postmenopausal Women (Epithelial Tumors - 90% of Ovarian Cancers) :
CA-125 : Serum marker elevated in serous epithelial ovarian carcinoma. Note: CA-125 is non-specific in premenopausal women (elevated in endometriosis, fibroids, PID, pregnancy).
HE4 (Human Epididymis Protein 4): Complementary marker for epithelial ovarian cancer.
Adolescents & Young Women <30 Years (Germ Cell & Sex Cord Tumors) :
Dysgerminoma : Elevated LDH (Lactate Dehydrogenase).
Yolk Sac Tumor (Endodermal Sinus Tumor): Elevated AFP (Alpha-Fetoprotein).
Choriocarcinoma : Elevated β-hCG .
Granulosa Cell Tumor (Sex cord-stromal): Secretes Estrogen and Inhibin B ; presents with precocious puberty or postmenopausal bleeding.
Sertoli-Leydig Cell Tumor : Secretes Testosterone ; presents with rapid virilization (hirsutism, voice deepening, clitoromegaly).
Risk of Malignancy Index (RMI)
SOGC recommends using RMI to triage pelvic masses for gynecologic oncology referral: RMI = U × M × CA-125 \text{RMI} = U \times M \times \text{CA-125} RMI = U × M × CA-125
U U U = Ultrasound score (0, 1, or 3 based on multilocularity, solid areas, ascites, metastases, bilateral lesions).
M M M = Menopausal status (1 = Premenopausal; 3 = Postmenopausal).
CA-125 \text{CA-125} CA-125 = Serum concentration in U/mL.
RMI >200 : Indicates high malignancy risk and mandates referral to a Gynecologic Oncologist .
Vulvar Carcinoma & Lichen Sclerosus
Vulvar Squamous Cell Carcinoma : Accounts for 90% of vulvar cancers. Typically presents in postmenopausal women with chronic vulvar pruritus, pain, or a visible vulvar mass/ulcer.
Mandatory Diagnostic Procedure : Vulvar Punch Biopsy (Keyes punch) under local anesthesia for any persistent or suspicious vulvar lesion.
Lichen Sclerosus : Chronic autoimmune dermatosis characterized by porcelain-white crinkled plaques, loss of vulvar architecture (resorption of labia minora), and perianal "figure-of-eight" distribution. Carries a 4–5% risk of malignant transformation to SCC . Treatment: High-potency topical corticosteroids ( Clobetasol propionate 0.05% ointment daily for 3 months, then maintenance).
SOGC Clinical Practice Pearls & Exam Traps
⚠️ EXAM TRAP : CA-125 is NOT a screening test for ovarian cancer in asymptomatic women! It is utilized for evaluating suspicious adnexal masses in postmenopausal women and for monitoring treatment response in known epithelial ovarian cancer.
🩺 CLINICAL SCENARIO : An 18-year-old female presents with acute right lower quadrant pain. Ultrasound reveals an 8 cm solid and cystic right adnexal mass. Serum lab results show: β-hCG negative, CA-125 18 U/mL, and Alpha-Fetoprotein (AFP) 4,200 IU/mL. What is the diagnosis?
Diagnosis : Yolk Sac Tumor (Endodermal Sinus Tumor) of the ovary, a malignant germ cell tumor characteristic of young females that specifically produces elevated serum AFP.